Service Process
Service Highlights
Integrated PCC-to-IND services and efficient project delivery
Integration of the ten functional modules and supports from an experienced project management team. Only gene sequences are required for the delivery of IND filing package and clinical samples in 12 months.
Over 30 ongoing PCC-to-IND projects and rich project experiences
Drug modalities include monoclonal antibodies, multispecific antibodies, fusion proteins, ADCs, etc. Indications cover hematological malignancies, solid tumors, autoimmunity, eye diseases, metabolism disorders, infections and other diseases.
Antibody titer up to 12 g/L, ensures outstanding competitive advantage
The average antibody expression titer is 5~6 g/L, and the highest is 12 g/L, which is much higher than the industry average level of 3~5 g/L. High titer can significantly reduce the unit production cost and enhance the product market competitiveness.
Four sets of authorized host cells lines for flexible selection
Four sets of commercial authorized host cells of ThermoFisher, HORIZON, MERCK, and QuaCell are optional to match clients' needs for process, protein post-translational modification and licensing terms.
Service Content
Cases Study
Two monoclonal antibodies from Sanyou have received the IND approval, one bispecific antibody has entered the IND application process and one bispecific antibody is about to enter the IND stage. In addition, 9 drugs entered the PD and QC stages. These drugs cover a wide range of indications, including COVID-19, solid tumors, hematological malignancies, eye diseases, and autoimmune diseases.
Achievements
Inquriy
Inquiry